AIMS: To examine the prognostic relevance of c-kit expression in human osteosarcomas and to evaluate the mutation status in exon 9 and exon 11 of the c-kit gene. METHODS: c-kit expression was examined in 100 human osteosarcomas by immunohistochemistry using paraffin embedded tumour tissues, and capillary sequencing of genomic DNA was performed to search for mutations in exons 9 and 11 of the c-kit gene. RESULTS: 20 osteosarcomas showed c-kit expression ranging from 5% to 90% (mean 5.9%; SD 16.74%). Furthermore, DNA sequences of exon 9 and exon 11 of the c-kit gene were not altered in these tumours. Overall and disease free survival analysis did not reveal any differences between patients with osteosarcoma with c-kit expression and those with c-kit negative tumours. CONCLUSIONS: C-kit expression is not a prognostic marker in patients with osteosarcoma. The protein expression is not linked to mutations in exon 9 or exon 11 of the c-kit gene. Therefore, these exons may not function as targets for treatment modalities based on the suppression of c-kit tyrosine kinase activity.
AIMS: To examine the prognostic relevance of c-kit expression in humanosteosarcomas and to evaluate the mutation status in exon 9 and exon 11 of the c-kit gene. METHODS:c-kit expression was examined in 100 humanosteosarcomas by immunohistochemistry using paraffin embedded tumour tissues, and capillary sequencing of genomic DNA was performed to search for mutations in exons 9 and 11 of the c-kit gene. RESULTS: 20 osteosarcomas showed c-kit expression ranging from 5% to 90% (mean 5.9%; SD 16.74%). Furthermore, DNA sequences of exon 9 and exon 11 of the c-kit gene were not altered in these tumours. Overall and disease free survival analysis did not reveal any differences between patients with osteosarcoma with c-kit expression and those with c-kit negative tumours. CONCLUSIONS:C-kit expression is not a prognostic marker in patients with osteosarcoma. The protein expression is not linked to mutations in exon 9 or exon 11 of the c-kit gene. Therefore, these exons may not function as targets for treatment modalities based on the suppression of c-kit tyrosine kinase activity.
Authors: Jay S Wunder; Nalan Gokgoz; Robert Parkes; Shelley B Bull; Sasha Eskandarian; Aileen M Davis; Chris P Beauchamp; Ernest U Conrad; Robert J Grimer; John H Healey; David Malkin; D C Mangham; Michael J Rock; Robert S Bell; Irene L Andrulis Journal: J Clin Oncol Date: 2005-03-01 Impact factor: 44.544
Authors: Michelle B Mintz; Rebecca Sowers; Kevin M Brown; Sara C Hilmer; BethAnne Mazza; Andrew G Huvos; Paul A Meyers; Bonnie Lafleur; Wendy S McDonough; Michael M Henry; Keri E Ramsey; Cristina R Antonescu; Wen Chen; John H Healey; Aaron Daluski; Michael E Berens; Tobey J Macdonald; Richard Gorlick; Dietrich A Stephan Journal: Cancer Res Date: 2005-03-01 Impact factor: 12.701
Authors: M Debiec-Rychter; H Dumez; I Judson; B Wasag; J Verweij; M Brown; S Dimitrijevic; R Sciot; M Stul; H Vranck; M Scurr; A Hagemeijer; M van Glabbeke; A T van Oosterom Journal: Eur J Cancer Date: 2004-03 Impact factor: 9.162
Authors: Luciana N O Miiji; Antonio S Petrilli; Sebastian Di Cesare; Alexandre N Odashiro; Miguel N Burnier; Silvia R de Toledo; Reynaldo Jesus Garcia; Maria Teresa S Alves Journal: Int J Clin Exp Pathol Date: 2011-11-03
Authors: Amit S Adhikari; Neeraj Agarwal; Byron M Wood; Constance Porretta; Bernardo Ruiz; Radhika R Pochampally; Tomoo Iwakuma Journal: Cancer Res Date: 2010-05-11 Impact factor: 12.701